KDR and neoplasm: These effects are mediated by the binding of VEGF to the vascular endothelial growth factor receptors (VEGFR), inhibiting receptor tyrosine kinase activation and downstream molecules, or occluding fragile tumour vasculature by vascular disrupting agents [24,25].